JUMP TO CONTENT

How has the pharmaceuticals industry changed in the last decade?

Posting date: 23/04/2020
Author: Inside ICON
The pharmaceuticals industry has been revolutionised over the last decade due to advances in technology and globalisation – and with it have come changes in clinical research. However, the US has maintained its majority share of the market and oncology remains the most valuable branch of therapy.

As for the public’s involvement, they’re becoming increasingly aware of the drugs they’re being prescribed which has pushed pharma companies to develop a more personalised level of treatment in the form of precision medicine. These factors are the key driving forces behind the growth of the industry over the last decade and we only expect this to continue, which means the future is bright for clinical research professionals.

Here’s an overview of an exciting decade in pharmaceuticals.

Digital is revolutionising pharmaceuticals

Like every industry, pharmaceuticals has been transformed by digital technologies. Predictive analytics, big data analytics and AI-based tools have given companies the tools they need to redesign their business processes. Using this new information to create a revived business model means that companies can produce drugs faster than ever before while artificial intelligence has enabled us to improve a patient’s responsiveness to drugs. The industry hasn’t missed out on tapping into the app market – according to Deloitte, from 2013 to 2016 pharma companies tripled the number of apps they developed. This is one example of how we’ve seen pharma shift towards being more patient-centric as these apps allow the public the be more in control of their health and engage better with companies on patient platforms.

Further to this, the current pandemic has transformed the industry at all levels, leaving many questions, such as, 'Could remote decentralised clinical trials be the future?'

Globalisation of pharma

As we entered the 2010s, we witnessed products for drugs being sourced and manufactured internationally, then sold on a global market platform – this globalisation is a first for the pharmaceuticals industry. Before this decade there were several R&D hubs but from 2010 onwards this shifted towards a global outsourcing of research capabilities and the mass manufacturing of drugs for both the developed and developing markets. This globalisation means that the CIVET group - Cambodia, Indonesia, Vietnam, Egypt and Turkey - now have access to drugs, which is one major contributor to the growth of the pharmaceutical industry.

A decade of growth for pharma

It was announced in 2018 that the global pharmaceuticals market had cashed $1.2 trillion in revenue, which is a soaring 35% increase in just 10 years. America continues to have the biggest impact on this figure for various reasons, including lower taxes on drugs, a drop in prices and more relaxed regulatory barriers for new drugs.

Globally, we’re experiencing an ageing population who are presenting more complex health conditions which need medication. In 2010 China was the third largest pharmaceutical market and since then they’ve climbed up to second place, only behind the US, which remains a leader in clinical research. A key reason for this rise in the ranks is that in 2019, between August and November, their drug reimbursement list added 218 new medicines.

As the list continues to grow we expect the Chinese pharmaceuticals market to continue booming and helping the overall marketing grow from strength to strength.

Prescription medicines

In 2019 spending on prescription drugs hit US$500 billion, reflecting a two-fold increase in the last 10 years. Yet, according to Market Watch, 2019 also marked the first time in 47 years the price of prescription medicine has dropped, falling 6% lower than the price in 2010. The makeup of these drugs has transformed over the decade too, starting as small molecule or biologics and switching to in silico in 2010. This was a step towards developing treatments that were personalised for each patient and enabled the introduction of cell-based and gene-based therapies in 2011 and 2012 respectively.

The advent of precision medicine

Precision medicine considers a person’s genes, environment and lifestyle to predict which treatment will be most effective. The defining feature of this practice of medicine is the focus on genomic data to design the specific treatment paths - in other words, the study of how a person will respond to a drug based on their genetic makeup.

The advent of precision medicine has allowed the development of effective and safe medication that is tailored to the individual, thereby helping to improve the health of people who are not responding to standardised options. But pharma companies are only just scratching the surface of precision medicine as it’s expected that by 2025 the market will be worth US$85.5 billion.

Join us for another exciting decade in pharmaceuticals

If you want to work with the world’s top pharma, biotechnology and medical device companies, bring your career to ICON. We’re a leading clinical research organisation and are always looking for talented and driven people to help us become the partner of choice in drug development, particularly those who are clinical research associates.

View our clinical research jobs or browse all job categories to narrow your search.


List #1

Related jobs at ICON

(Sr) Project Manager, Feasibility Site Activation

Salary

Location

Mexico, Mexico City

Location

Sao Paulo

Santiago

Bogota

Mexico City

Lima

Remote Working

Remote or Office

Business Area

ICON Full Service & Corporate Support

Job Categories

Project Management

Job Type

Permanent

Description

As a Project Manager, Feasibility and Site Activation (FSA) at ICON, you will be responsible for planning and manage Feasibility and Site Activation (FSA) activities for assigned clinical studies.What

Reference

JR148391

Expiry date

01/01/0001

Florencia  Borello Taiana Read more Shortlist Save this role
Talent Acquisition Business Partner - Fixed term

Salary

Location

Brazil, Sao Paulo

Department

Full Service - Corporate Support

Location

Sao Paulo

Remote Working

Hybrid

Business Area

ICON Full Service & Corporate Support

Job Categories

Human Resources

Talent Acquisition

Job Type

Temporary Employee

Description

We are currently seeking a Talent Acquisition Business Partner to join our diverse and dynamic team. As a Talent Acquisition Business Partner at ICON, you will be responsible for executing recruitment

Reference

JR145978

Expiry date

01/01/0001

Florencia  Borello Taiana Read more Shortlist Save this role
Clinical Research Associate 3

Salary

Location

Turkey, Istanbul

Location

Istanbul

Remote Working

Remote

Business Area

ICON Strategic Solutions

Job Categories

Clinical Monitoring

Job Type

Permanent

Description

We are currently seeking a Senior Clinical Research Associate (CRA) to join our diverse and dynamic team. As a Senior CRA at ICON Plc, you will play a critical role in overseeing and managing clinical

Reference

JR147623

Expiry date

01/01/0001

Tuba Su

Author

Tuba Su
Tuba Su

Author

Tuba Su
Read more Shortlist Save this role
Senior Nonclinical Editor

Salary

Location

US, Blue Bell (ICON)

Location

Reading

Blue Bell

Remote Working

Remote

Business Area

ICON Strategic Solutions

Job Categories

Marketing & Media

Job Type

Permanent

Description

As a Senior Medical Editor at ICON, you will be responsible for ensuring the accuracy, clarity, and quality of scientific documents and publications related to clinical trials.What You Will Do:This po

Reference

JR148457

Expiry date

01/01/0001

Melissa Benner Read more Shortlist Save this role
View all
List #1

Related stories

Headshot of male
25 Years in Clinical Operations at ICON: Ricardo Cortizo Justo Q&A

Teaser label

Our People

Content type

Blogs

Publish date

04/08/2026

Summary

Ricardo Cortizo Justo, Director of Clinical Operations and Site Head for Paris at ICON plc, recently marked an exceptional milestone of 25 years with the organisation. Over the course of his career, R

Teaser label

Ricardo shares insights from 25 years at ICON, covering clinical operations, leadership, and career development.

Read more
Heartbeat vitals on monitor
Central Monitoring vs On Site Monitoring

Teaser label

Industry

Content type

Blogs

Publish date

04/03/2026

Summary

Understanding Central Monitoring vs On Site Monitoring Monitoring is a core component of clinical trial oversight. It ensures that studies are conducted in line with the protocol, that data is re

Teaser label

Learn the difference between central monitoring and on site monitoring and how both support patient safety and data quality.

Read more
middle aged male wearing shirt
Francis' Journey back to ICON

Teaser label

Our People

Content type

Blogs

Publish date

03/26/2026

Summary

Why Francis returned to ICON: building a long-term career in clinical research Francis Kayamba is a Clinical Research Associate based in Johannesburg, South Africa. He first joined ICON in February

Teaser label

Francis Kayamba shares what drew him back to ICON and how the sponsor-embedded model works.

Read more
View all
List #1

Recently viewed jobs

View Jobs

Browse popular job categories below or search all jobs above